Results 261 to 270 of about 277,119 (298)
, 2007 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Mechanisms of drug resistance in HCC
Hepatology, 2023HCC comprises ∼80% of primary liver cancer. HCC is the only major cancer for which death rates have not improved over the last 10 years. Most patients are diagnosed with advanced disease when surgical and locoregional treatments are not feasible or ...
Alexandra D. Ladd +3 more
semanticscholar +1 more source
Hepatology, 2021
Recently, clinical trials of lenvatinib plus pembrolizumab in HCC have displayed an impressive objective response rate. This study aimed to clarify the mechanism for optimal patient selection.
Chenhe Yi +12 more
semanticscholar +1 more source
Recently, clinical trials of lenvatinib plus pembrolizumab in HCC have displayed an impressive objective response rate. This study aimed to clarify the mechanism for optimal patient selection.
Chenhe Yi +12 more
semanticscholar +1 more source
Journal of Hepatology, 2012
Hepatocellular carcinoma (HCC) is a highly prevalent and lethal neoplasia, the management of which has significantly improved during the last few years. A better knowledge of the natural history of the tumor and the development of staging systems that stratify patients according to the characteristics of the tumor, the liver disease, and the ...
Alejandro Forner +4 more
openaire +2 more sources
Hepatocellular carcinoma (HCC) is a highly prevalent and lethal neoplasia, the management of which has significantly improved during the last few years. A better knowledge of the natural history of the tumor and the development of staging systems that stratify patients according to the characteristics of the tumor, the liver disease, and the ...
Alejandro Forner +4 more
openaire +2 more sources
Reviews on Recent Clinical Trials, 2008
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with increasing incidence in the Western World. In contrast to most other malignancies, only surgical and local ablative therapeutic options have shown efficacy in patients with HCC. Systemic chemotherapy has failed to show a substantial benefit for these patients.
Tim F. Greten +2 more
openaire +3 more sources
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with increasing incidence in the Western World. In contrast to most other malignancies, only surgical and local ablative therapeutic options have shown efficacy in patients with HCC. Systemic chemotherapy has failed to show a substantial benefit for these patients.
Tim F. Greten +2 more
openaire +3 more sources